Industry Perspectives

Bionova Scientific expands capacity and enters advanced therapies market

Cytiva’s Fast Trak process development services will accelerate Bionova’s production processes while ensuring compliance with stringent regulatory standards
Written byCytiva and Bionova Scientific
| 2 min read
Two scientists in full cover interact with a machine in a lab

CREDIT: Cytiva

Register for free to listen to this article
Listen with Speechify
0:00
2:00

Bionova Scientific, a contract development and manufacturing organization (CDMO), is entering the advanced therapy manufacturing space. The company is installing its third FlexFactory manufacturing platform from Cytiva, a Danaher company and a leader in the life sciences industry, to help meet the surging demand for advanced therapies, while maintaining their core monoclonal antibody (mAb) business. Bionova will also use Cytiva’s Fast Trak process development services to help advance their entry into genomic medicines.

Fabio Fonseca, Ph.D. Senior Director, pDNA Process Development, Bionova Scientific, says: “Using Cytiva’s end-to-end solutions, we’ll have an exceptional platform to support the manufacture of genomic medicines. Together with our team and technology stack, we are well positioned to deliver plasmid DNA with speed, quality and patient safety.”

Ludovic Brellier, President of Hardware Solutions, Cytiva, says: “Our true value lies in our deep process expertise in accelerating our customer’s process development through to commercial manufacturing. Having the flexibility and support to scale while meeting strict regulatory compliance will help Bionova develop a competitive edge in a growing market.”

The FlexFactory platform for advanced therapies offers substantial benefits that reduce business risks, increase operational speed, faster product ramp-up, and enhance flexibility. Its built-in compliance features and robust quality controls helps improve regulatory adherence and minimize production issues, while its modular setup allows rapid adaptation to market shifts. Cytiva’s Fast Trak process development services will help Bionova accelerate their molecule through clinical development.

Bionova’s new facility in The Woodlands, Texas celebrated its grand opening on May 29, 2025, with the new FlexFactory slated for delivery in Q3 2025.

Find more information on the Cytiva FlexFactory manufacturing platform here.

Learn more about Bionova Scientific’s new offerings here.

>Cytiva, the drop logo, FlexFactory and Fast Trak are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
3D illustration of a protein complex composed of clustered spherical subunits arranged in a ring-like oligomeric structure, shown in shades of blue, cyan, and purple against a blue gradient background.
Automated mass photometry helps reveal the complex dynamics of protein oligomerization and the factors that govern protein assembly.
A 3D rendering illustrates a sandwich ELISA technique, where antigen detection is achieved between two layers of antibodies: a capture antibody and a detection antibody
Learn the key characteristics that determine whether an immunoassay generates accurate and reproducible data.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue